What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling
A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to stratify patient populations by elucidating the involvement of specific genes, proteins, and molecular alterations that give rise to their disease state. Therapies can then be aligned with patients most likely to benefit.
The challenge is that bioanalytical methods have been limited in their ability to probe this biology in a nontargeted fashion at a speed and scale that yields rapid impact, particularly when it comes to small molecule biomarker discovery – until now.
Download the infographic to see how Sapient’s next-generation, mass spectrometry-based technologies, combined with biocomputational support and an expansive Human Biology Database, multiplies the rate of untargeted biomarker discovery to maximize drug development success.